HomeQuestion

How do you approach neutropenia in patients being treated with obinutuzumab/venetoclax for CLL?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Is there therapeutic relevance for FLT3-ITD mutation in relapsed APML?

In patients with post-PV myelofibrosis who are ineligible for allogeneic stem cell transplant, how do you approach symptomatic splenomegaly refractory to splenic radiation and ruxolitinib?

If using the triplet AMPLIFY regimen with ven/acala/obin upfront, what do you then plan to use in 2nd line treatment of CLL?

How do you monitor and manage minimal residual disease (MRD) in patients with core-binding factor (CBF) AML who are in remission post-induction and consolidation therapy?

What is your preferred 1L treatment for newly diagnosed Del(17p)/TP53 mutation, high-risk CLL?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.